Galectin Therapeutics Inc.
NASDAQ:GALTBiotechnology
Healthcare
$2.98 +1.62%
+$0.05 today
- Market cap
- $196.25M
- Beta
- 0.49
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.40
52W Low $1.85High $7.13
Volume 0.23M
Average 0.32M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$23.88M
FY 2025 · Annual
Investing Cash Flow
$0.00
FY 2025 · Annual
Financing Cash Flow
$26.48M
FY 2025 · Annual
-15.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.53M) | (38.78M) | (41.07M) | (47.05M) | (30.84M) |
| Depreciation & Amortization | 41K | 32K | 33K | 37K | 53K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 2.87M | 2.26M | 2.45M | 1.66M |
| Change in Working Capital | 3.75M | 4.97M | 4.68M | 2.28M | 609K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.69M | 4.24M | 2.67M | (2.07M) | (6.04M) |
| Other Working Capital | 65K | 724K | 2.01M | 4.36M | 6.65M |
| Other Non-Cash Items | 351K | (147K) | 1.13M | 512K | 4.64M |
| Operating Cash Flow | (24.31M) | (31.06M) | (32.97M) | (41.77M) | (23.88M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 30M | 10M | 30M | 30M | 21M |
| Common Stock Issued | 6.81M | 0 | 0 | 1.23M | 5.48M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (171K) | 0 | 0 | (91K) | 0 |
| Other Financing Activities | 171K | 0 | 10.03M | 91K | 0 |
| Financing Cash Flow | 36.81M | 10M | 40.03M | 31.23M | 26.48M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 12.51M | (21.06M) | 7.07M | (10.54M) | 2.6M |
| Free Cash Flow | (24.31M) | (31.06M) | (32.97M) | (41.77M) | (23.88M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$30.8M
+ D&A$53.0K
+ Stock-Based Comp$1.7M
+ Deferred Tax$0
+ Working Capital$609.0K
+ Other Non-Cash$4.6M
= Operating Cash Flow-$23.9M
- Capex$0
= Free Cash Flow-$23.9M
Analysis
FY2025 free cash flow is -$23.9M. FCF conversion is 77.4% of net income. Operating cash flow was -$23.9M, with capex of $0. The largest bridge item is Other Non-Cash at $4.6M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| ARS | ARS filing | Oct 13, 2026 | |
| DEF 14A | DEF 14A filing | Oct 13, 2026 | |
| DEFA14A | DEFA14A filing | Oct 13, 2026 | |
| PRE 14A | PRE 14A filing | Oct 2, 2026 | |
| 10-Q | Quarterly report | Aug 14, 2026 |
Does GALT generate free cash flow?
Galectin Therapeutics Inc. (GALT) generated -$23.88M of free cash flow in fiscal 2025.
How much operating cash flow does GALT produce?
Operating cash flow was -$23.88M, before capital expenditures of $0.00.
Continue the stock analysis
Jump to another research area for this company.